Madrigal Pharmaceuticals stock jumps 3.95% as company promotes BSG Liverpool symposium

Traders Union
All News
Companies
Madrigal Pharmaceuticals rises 3.95% today

Highlights

MDGL exhibits near-term strength but faces upside resistance, consolidating between $481.50 and $509.00 amid two-way trade.
Momentum indicators show a mixed outlook, with sellers currently dominant but trend signals lacking clear direction.
A decisive move above $511.91 could trigger further gains toward the upper $520s, while a drop below $492.00 risks deeper retracement.

Short-term strength as gains capped by MA-50 resistance

MDGL is trading at $499.76, positioned just above the MA-20 ($496.99) and slightly higher than the MA-200 ($492.04), but still below the MA-50 ($511.91). This configuration shows emerging short-term strength above key moving averages, while medium-term pressure from the MA-50 limits further gains; the Ichimoku Kijun at $496.22 sits just below market price, acting as immediate support. Near-term support is marked by the Ichimoku Kijun ($496.22) and MA-200 ($492.04). Key support lies at MA-100 ($488.84), while near-term resistance is the MA-20 ($496.99), with the MA-50 ($511.91) as the next major resistance overhead.

Mixed momentum as weekly gains test top of recent range

Momentum signals on D1 are mixed: MACD flashes a sell, and ADX is neutral, indicating modest trend strength. Both RSI (44.75) and CCI (-62.41) suggest the asset is not overbought, with Stoch RSI near 58.11 pointing to a balanced state. BBP shows an oversold reading, signaling sellers are currently dominant. The Awesome Oscillator also indicates a sell, aligning with modest downward weekly momentum. MDGL has risen $18.99 (3.95%) over the past week, moving from a previous weekly close of $480.77; current price action is at the very top of the weekly range, and weekly volatility stands at 5.35%. The overall tone shows a recovery from last week's lows, with this week's move confirmed by a strong daily gain. In today's session, the stock surged nearly 4%, marking a notable upswing to challenge resistance.

Balanced outlook as consolidation favors range-bound price action

Looking ahead, the expected price range for the coming week is $481.50 to $509.00, which keeps MDGL within the upper third of its yearly band between the 52-week low of $275.00 and the high of $615.00. Using W1 signals, the probability of further gains is moderate (50%), given that only MA-50 on W1 and MACD on W1 signal buy, while both RSI and ADX remain neutral or bearish; the probability of a decline is equally likely. The baseline scenario calls for consolidation between support and resistance. A bullish break above $511.91 could open room toward the upper $520s, while a bearish scenario sees the price slipping under $492.00 toward MA-100 at $488.84. The proximity to immediate resistance and the split in momentum readings suggest active two-way trade, with no clear directional dominance at this stage.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Earlier, analysts noted that Madrigal Pharmaceuticals was exhibiting bullish momentum amid strong sector engagement and positive technical sentiment. In light of recent developments, investors should watch for sustained strength above near-term support as the prevailing scenario continues to favor upside, though vigilance is warranted for potential shifts in trend.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.